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Diabetes mellitus in dogs attending UK
primary-care practices: frequency, risk
factors and survival
Angela M. Heeley1* , Dan G. O’Neill1, Lucy J. Davison2, David B. Church2, Ellie K. Corless1 and Dave C. Brodbelt1
Abstract
Background: Diabetes mellitus (DM) is an important endocrine disorder of dogs. The objectives of this study were
to estimate prevalence and incidence of DM in dogs, and to explore risk factors for DM and the survival of DM
cases in primary-care clinics in the UK.
Results: A case-control study nested in the cohort of dogs (n = 480,469) aged ≥3 years presenting at 430
VetCompass clinics was used to identify risk factors for DM, using multivariable logistic regression. Overall 409 new
and 863 pre-existing DM cases (total 1272) were identified in 2016, giving an apparent annual prevalence of 0.26%
(95% confidence interval (CI): 0.25–0.28%), and an annual incidence risk of 0.09% (95%CI: 0.08–0.09%) in dogs aged
≥3 years. Factors associated with increased odds for DM diagnosis were all age categories > 8 years, female entire
dogs (odds ratio (OR): 3.03, 95% CI 1.69–5.44, p < 0.001) and male neutered dogs (OR: 1.99, 95% CI 1.18–3.34, p =
0.010) compared to male entire dogs, Border Terriers (OR: 3.37, 95% CI 1.04–10.98, p = 0.043) and West Highland
White Terriers (WHWT) (OR: 2.88, 95% CI 1.49–5.56, p = 0.002) compared to crossbreeds. Dogs that had received
previous glucocorticoid treatment (OR: 2.19, 95% CI 1.02–4.70, p = 0.044) and those with concurrent conditions
(documented obese, pancreatitis, hyperadrenocorticism) also had increased odds for DM diagnosis.
Cox regression modelling was used to evaluate factors associated with survival in the 409 incident DM cases in
2016. Increased hazard of death following diagnosis of DM was shown in dogs that were ≥ 10 years age, Cocker
Spaniels (HR: 2.06, 95% CI 1.06–4.01, p = 0.034) compared to crossbreeds, had a blood glucose (BG) level at
diagnosis > 40 mmol/L (HR: 2.73, 95% CI 1.35–5.55, p = 0.005) compared to < 20 mmol/L at diagnosis, or had
received previous glucocorticoid treatment (HR: 1.86, 95% CI 1.21–2.86, p = 0.005). Dogs at reduced hazard of death
included neutered dogs (HR: 0.58, 95% CI 0.42–0.79, p = 0.001), Border Collies (HR: 0.39, 95% CI 0.17–0.87, p = 0.022)
and those starting insulin treatment (HR: 0.08 95% CI 0.05–0.12, p < 0.001).
Conclusions: Certain breeds and concurrent health conditions are associated with an increased risk of DM. In
addition to certain signalment factors, a high BG level at diagnosis and prior glucocorticoid treatment were
adversely associated with survival of dogs with DM.
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Plain English summary
Diabetes mellitus (DM) is a serious disease that can
compromise the welfare of dogs. This study looked at
factors associated with the risk of dogs developing DM,
and also factors associated with how long they might
survive with the disease.
The study compared 409 dogs from UK primary-care
practice diagnosed with DM in 2016, with 818 dogs
without DM. Dogs that were more likely to be diagnosed
with DM included those that were older than 8 years, fe-
male dogs that were not neutered, male dogs that were
neutered, Border Terriers, West Highland White Ter-
riers (WHWTs), those who had previous been on gluco-
corticoid (steroid) medication, and those with other
health conditions such as obesity, pancreatitis or hypera-
drenocorticism. Conversely, Staffordshire Bull Terriers
(SBT), Shih-tzus and German Shepherd Dogs (GSDs)
were less likely to develop DM.
For the survival of dogs with DM, factors associated
with decreased survival included dogs > 10 years old at
diagnosis, Cocker Spaniels, those with very high blood
glucose readings at diagnosis with DM, or those who
had previously been on glucocorticoid (steroid) medica-
tion. Factors associated with increased survival included
dogs that were neutered, Border Collies and dogs start-
ing insulin treatment.
Background
Diabetes mellitus (DM) is a relatively common endocrino-
pathy of dogs, with an estimated prevalence of approxi-
mately 0.32–0.36% [1–3]. Clinical DM in dogs is
characterised by the loss of pancreatic islet cells resulting
in insulin deficiency and persistent hyperglycaemia, result-
ing in clinical signs including polyuria, polydipsia, poly-
phagia and weight loss [4, 5]. Both genetic and
environmental factors are implicated in the development
of this disease [6]. Although the exact pathogenesis lead-
ing to islet cell loss is often unclear [6], and is likely to be
heterogeneous, there are thought to be similarities be-
tween some cases of DM in dogs and type 1 diabetes mel-
litus (T1DM) in humans [7–9]. The incidence of T1DM
has been increasing worldwide [10], and the speed of this
rise suggests it is not solely related to genetic factors. The
prevalence of DM in dogs is reported to be increasing, up
by 79.7% since 2006 in the US [11, 12], and highlights a
need for a greater understanding of the current frequency
and risk factors in the development of the disease.
Factors reported to be associated with the develop-
ment of DM in dogs include genetics, age, sex, neutering
status, obesity, drug therapy, infection and concurrent
disease [9, 13]. Juvenile-onset diabetes before 1 year of
age in dogs is uncommon [1], and is more likely to have
a familial element [14]. DM is more commonly diag-
nosed in middle-aged to older dogs [8, 11, 15], typically
in dogs over 5 years of age. Although reported breed
predispositions vary between countries, certain breeds
appear predisposed including Samoyeds [7, 11, 16, 17],
miniature schnauzers [7, 11, 17], Cairn terriers [11, 13,
15, 17–19] and Yorkshire terriers [2, 14]. Conversely
German Shepherd Dogs (GSD), Golden retrievers [2, 17]
and Boxers appear at a reduced risk [3, 13, 15, 16].
There has been inconclusive evidence for sex and neuter
status as risk factors, likely related to the varying neuter-
ing practices internationally. Where it is not common
practice to neuter female dogs, dioestrus-associated dia-
betes is more common. This is related to the antagonising
effects on insulin from progesterone, as well as growth hor-
mone released from the canine mammary glands under the
influence of progesterone [20]. Some studies show females
at increased risk compared to males [11, 15, 16, 21], and
neutered males at increased risk compared to entire males
[2, 3, 11]. However it is unclear whether sex alone is associ-
ated with DM [1–3, 14, 19, 22], and some studies also failed
to identify association with neutering, though may be lim-
ited by their small sample sizes [19, 22].
Obesity has been associated with both human type 2
diabetes mellitus (T2DM), and feline diabetes [9], but
there is limited evidence about the role of obesity in the
development of DM in dogs [6, 23]. Obesity-induced insu-
lin resistance has been documented in dogs, but it appears
that dogs are resistant to developing type 2 diabetes [24].
A number of studies have identified being overweight/
obese as risk factors for DM in dogs [2, 25, 26]. Conversely
one small study reported an association with underweight
dogs, but because body condition score (BCS) was
assessed by the veterinarian at the time of diagnosis, this
may reflect consequential weight loss associated with the
DM rather than as a true predictive risk factor [19].
Diabetes mellitus in dogs has been associated with co-
morbidities such as hyperadrenocorticism, urinary tract
infections (UTI), dermatitis, otitis, pancreatitis and
hypothyroidism [2, 3, 14, 17, 27]. Hyperadrenocorticism
is the most commonly associated endocrinopathy with
DM [17, 28, 29], and has been identified as a risk factor
[2, 16], which is most likely related to the cortisol antag-
onism of insulin. Immune-mediated insulitis and exo-
crine pancreatic disease are also thought to play a role in
the pathogenesis of DM [1, 30, 31] and, although the
exact relationship between the two diseases is not en-
tirely clear [32], pancreatitis is commonly found concur-
rently with DM [2, 3, 17, 33, 34]. One study found
pancreatitis was associated with increased risk of DM,
and with decreased survival [2].
The few studies that have reported on the survival of
dogs with DM have provided little agreement on the me-
dian survival time (MST) [2, 16, 34, 35]. A study of in-
sured dogs in Sweden reported a MST of 57 days from
the date of the first insurance claim across all cases,
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increasing to 2 years for dogs surviving at least 1 day
[16]. Comparatively, a study of English primary-care
practices and a study from a referral hospital in Italy re-
ported MST as 17.3 months [2] and 32 months [34] re-
spectively. A study surveying veterinarians reported that
1 in 10 dogs were euthanised at diagnosis and another 1
in 10 euthanised within 1 year, most commonly due to
concurrent conditions, cost considerations and age [35].
Little is known about the risk factors for survival in dogs
with DM, particularly in a primary care setting. Pancrea-
titis and old age have been associated with a higher hazard
of death, whereas neutered and insured dogs had lower
hazard [2]. Another study found no association with age,
nor with a previous diagnosis of pancreatitis, but breed af-
fected survival time [16]. However these studies have been
limited by relatively short follow up time [2, 16], or being
restricted to referral populations [34], and none have in-
vestigated the prognostic impact of the initial manage-
ment of the condition on subsequent survival.
The aim of this study was to estimate prevalence and
incidence of DM in a large population of dogs under pri-
mary veterinary care in the UK, and to investigate risk
factors for DM and the survival of DM cases. Secondary
aims were to describe the current diagnostic processes
and early DM management as well as exploring associa-
tions between these and survival. A greater understand-
ing of the risk factors involved in the development of
DM, and prognostic indicators for survival, can help in-
form genetic studies and allow population stratification
for clinical trials as well as aiding primary care clinicians
in identifying individuals at risk and in providing owners
with prognostic information.
Results
The study population consisted of 480,469 dogs aged ≥3
years on 01/01/2016 under veterinary care at 430
primary-care UK-wide VetCompass practices during the
study period. The median age was 6.7 years (range: 3.0–
20.2 years), 48.2% (231,524) were female, and 56.4%
(271,068) were neutered. Within this population, 409
new (incident) and 863 pre-existing DM cases (total
1272) were identified in 2016, giving an apparent annual
prevalence of 0.26% (95% confidence interval (CI): 0.25–
0.28%), and an annual incidence risk of 0.09% (95%CI:
0.08–0.09%) in dogs aged ≥3 years.
Descriptive statistics
Of the 409 incident DM cases in 2016, 48.9% (200) were
female, and 70.7% (289) were neutered, 77.5% (317) were
classified purebred and 32.5% (133) were insured. The
median age at diagnosis was 10.0 years (range: 3.2–18.0
years). For those dogs where diagnostic test information
was recorded electronically (392), nearly all diagnoses in-
cluded blood testing (96.9%, 380/392), and the majority
had a combination of blood testing and urinalysis
(76.0%, 298) (Table 1). Dogs that were ketotic at diagno-
sis (32.8%, 134), and dogs with cataracts present within
3 months after diagnosis (32.8%, 134) both accounted for
approximately a third of cases each. Recorded blood glu-
cose (BG) levels at diagnosis ranged between 12.2–51.7
mmol/L, median 28.1 mmol/L. Most dogs (90.1%, 362)
were started on insulin treatment, most commonly twice
daily injections (68.3%, 224). There was no information
on insulin treatment for 1.7% [7] of dogs. Of those dogs
not receiving insulin treatment (9.8%, 40), only 17.5% (7/
40) survived > 7 days, and of these dogs only 1 received
another drug (acarbose). There were 16.1% (66) of dogs
hospitalised at diagnosis, and only 5.9% [24] were re-
ferred for advanced management.
Where monitoring of DM in the first 3 months was re-
corded (88.3%, 361), 90% primarily involved blood test-
ing (324/361), which consisted of haematology,
biochemistry, BG measurements, and/or fructosamine
analyses. The most common monitoring approaches
were home or practice BG curves (70.6%, 255) and/or
spot BG (68.4%, 247). Only 15 (4.2%) of the dogs were
managed with spot BG alone and no other tests. Almost
half of dogs (44.3%, 160) had urinalysis as part of their
monitoring, and a similar percentage (41.3%, 149) had a
diet change recommended. “Other” management tech-
niques were used in 35.5% (128) of cases, and in most
cases, this was fluid therapy.
Case-control study
The results of univariable logistic analysis are described
in Table 2. There were strong associations with the fol-
lowing variables: age at diagnosis, neutering status, sex
combined with neutering status, bodyweight, breed,
obesity, prior treatment with glucocorticoids, a concur-
rent diagnosis of hyperadrenocorticism or pancreatitis,
insurance status and veterinary group. Purebred status
was associated at p < 0.2, and sex alone was not associ-
ated with diagnosis of DM.
The final multivariable model (Table 3) included eight
variables, and appeared to explain the data well (Hosmer-
Lemeshow p = 0.999). Clustering at clinic level was not
significant when clinic ID was added as a random effect
(p = 0.497). Veterinary group confounded associations
with age at diagnosis, sex combined with neutering, con-
current conditions, and breed, and was therefore included
as a fixed effect. After adjusting for the other variables in
the model, an increased odds for DM diagnosis was seen
with age > 8 years old (OR peaking at 10 to < 13 years old),
and female entire dogs (OR: 3.03, 95% CI 1.69–5.44, p <
0.001) and male neutered dogs (OR: 1.99, 95% CI 1.18–
3.34, p = 0.010) compared to male entire dogs. With male
entire dogs as a baseline category in the sex-neuter vari-
able there was no significant difference between the ORs
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Table 1 Diagnostics and management techniques for dogs diagnosed with diabetes mellitus
Number of cases (%)
(n = 409)
Diagnostic procedures (multiple tests allowed per dog)
Urinalysis 310 (75.8%)
Blood Glucose (BG) 356 (87.0%)
Fructosamine 169 (41.3%)
Blood (unspecified) 330 (80.7%)
Othera 36 (8.8%)
Diagnostic tests not recorded 17 (4.2%)
Blood glucose level at diagnosis
Median (range) mmol/L 28.1 (12.2–51.7)
< 20 mmol/L 34 (8.3%)
20 to < 30mmol/L 108 (26.4%)
30 to < 40mmol/L 83 (20.3%)
> 40 mmol/L 23 (5.6%)
Level unrecorded 161 (39.4%)
Ketotic at diagnosis
Ketotic 134 (32.8%)
Not ketotic 263 (43.8%)
No record of assessing ketones 96 (23.5%)
Insulin treatment
Dog started on insulin 362 (88.5%)
Dog not started on insulinb 40 (9.8%)
Insulin treatment unknown 7 (1.7%)
Insulin regime
Once a day 67 (16.4%)
Twice a day 224 (54.8%)
> 2x daily injections 24 (5.9%)
Constant Rate Infusion 13 (3.2%)
Unable to determine initial insulin regime 81 (19.8%)
Cataracts present
Cataracts diagnosed 134 (32.8%)
Not recorded 275 (67.2%)
Hospitalised at diagnosis
Dog hospitalised 66 (16.1%)
No evidence of hospitalisation 343 (83.9%)
Number of days hospitalised
Median (range) 0 (0–12)
0 days 343 (83.9%)
1–3 days 49 (12.0%)
4+ days 17 (4.2%)
Referred for advanced management
Dog referred 24 (5.9%)
Not referred 385 (94.1%)
Management methods first 3 months (multiple methods allowed per dog) n = 361
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for female entire dogs (OR: 3.03, 95% CI 1.69–5.44) and
female neutered dogs (OR: 1.36, 95% CI 0.80–2.31).
Border Terriers (OR: 3.37, 95% CI 1.04–10.98, p = 0.043)
and West Highland White Terriers (WHWT) (OR: 2.88,
95% CI 1.49–5.56, p = 0.002) compared to crossbreeds
were also associated with increased odds for DM, as were
those documented obese (OR: 2.71, 95% CI 1.63–4.52,
p < 0.001), or had a concurrent diagnosis of pancreatitis
(OR: 1085.19, 95% CI 36.36–32,390.61, p < 0.001) or
hyperadrenocorticism (OR: 11.28, 95% CI 2.41–52.73, p =
0.002). Compared to crossbreds, breeds with reduced odds
of DM included Staffordshire Bull Terriers (SBT) (OR:
0.42, 95% CI 0.18–0.98, p = 0.046), Shih-tzu (OR: 0.20,
95% CI 0.04–0.96, p = 0.045) and German Shepherd Dogs
(GSD) (OR: 0.08, 95% CI 0.01–0.74, p = 0.025).
Survival analysis
There were 252 (61.6%) deaths from all-cause mortality
prior to February 2020; of these, 147 (58.3%) were directly
attributable to DM and 233 (92.5%) were euthanised.
More than one reason was often given for a euthanasia de-
cision, and the most frequent reason cited was worsening
of DM clinical signs, cited in 58.4% (136/233) of euthan-
asia decisions (Table 4). This was closely followed by con-
tributory conditions which were cited in 57.1% (133/233)
of euthanasia decisions. Contributory conditions most fre-
quently included ocular disorders, contributing to 14.2%
(33/233) of euthanasia decisions, followed by pancreatitis,
neoplasia and non-specific poor quality of life, each con-
tributing to 7.3% (17/233) of all euthanasia decisions.
Median survival time from diagnosis for all dogs was 15.6
months (95% CI: 10.4–20.0), and for those surviving at least 7days
post DM diagnosis, MST was 20.2months (95% CI: 16.6–24.7).
The results from univariable cox regression are de-
scribed in Table 5. There were strong associations (p ≤
0.001) with survival for the following variables: age, neu-
tering status, insulin treatment, and monitoring methods
that included BG curves at the practice, spot BG,
fructosamine measurements or a recommended diet
change. Other variables associated at p < 0.2 included:
sex, combined sex and neuter status, insurance, breed,
being ketotic at diagnosis, prior glucocorticoid treat-
ment, obesity, BG level at diagnosis, and monitoring
methods including bloods (unspecified) and urinalysis.
The final multivariable model showed survival to be as-
sociated (p < 0.05) with age, neutering status, insulin treat-
ment, prior glucocorticoid treatment, and BG level at
diagnosis (Table 6). Dogs within the following categories
showed increased hazard of death following diagnosis of
DM: both age categories ≥10 years of age compared to
those aged 3 - < 8 years (10 - < 13 years HR: 2.12, 95% CI
1.42–3.18; > 13 years HR: 2.02, 95% CI 1.17–3.49), Cocker
Spaniels (HR: 2.06, 95% CI 1.06–4.01, p = 0.034) com-
pared to crossbreeds, a BG level at diagnosis > 40mmol/L
(HR: 2.75, 95% CI 1.35–5.57, p = 0.005) compared to < 20
mmol/L at diagnosis, or previous glucocorticoid treatment
(HR: 1.83, 95% CI 1.20–2.80, p = 0.005). Factors associated
with reduced hazard of death were neutered dogs (HR:
0.56, 95% CI 0.42–0.78, p < 0.001), Border Collies (HR:
0.39, 95% CI 0.17–0.87, p = 0.022) and dogs starting insu-
lin treatment (HR: 0.08 95% CI 0.05–0.12, p < 0.001). Initi-
ation of insulin treatment was associated with a variety of
management methods in the first 3 months. To avoid col-
linearity, only insulin treatment was included in the final
model. However the following management methods were
all associated with increased survival when substituting
them for insulin treatment and after adjusting for the
other variables in the final model: BG curves at the
practice (HR: 0.52, 95% CI 0.40–0.68, p < 0.001), recom-
mended diet change (HR: 0.61, 95% CI 0.46–0.81, p =
0.001), fructosamine measurements (HR: 0.63, 95% CI
0.48–0.84, p = 0.002) and spot BG measurements (HR:
0.67, 95% CI 0.51–0.89, p = 0.004).
The clinic ID frailty term in the final multivariable
model was not statistically significant (P = 0.497). Veter-
inary group confounded both neutering and breed
Table 1 Diagnostics and management techniques for dogs diagnosed with diabetes mellitus (Continued)
Number of cases (%)
(n = 409)
Home blood glucose measurements 45 (12.5%)
Blood glucose curve practice 234 (64.8%)
Fructosamine 135 (37.4%)
Spot blood glucose 247 (68.4%)
Bloods (unspecified) 110 (30.5%)
Urinalysis 160 (44.3%)
Recommended diet change 149 (41.3%)
Otherc 128 (35.5%)
Diagnostics and management for dogs aged 3 years and older diagnosed with diabetes mellitus in UK primary-care practices in 2016.
a The majority of “other” tests (91.7%, 33 dogs) were imaging
b Dogs not started on insulin included those where the owner opted for euthanasia, or specifically declined insulin treatment
c “Other” management included 92.2% (118) fluid therapy, 10.2% [13] imaging
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Table 2 Descriptive and univariable logistic regression results
Variable Case (%) n = 409 Control (%) n = 818 Odds Ratio 95% CIa Category
P-value
Variable
P-value
Age Median (range) 10.00 (3.16–18.00) 7.12 (3.07–17.25) < 0.001
Age at diagnosis
3 to < 8 years 77 (18.8%) 464 (56.7%) Base < 0.001
8 to < 10 years 124 (30.3%) 153 (18.7%) 4.88 3.48–6.85 < 0.001
10 to < 13 years 165 (40.3%) 140 (17.1%) 7.10 5.11–9.88 < 0.001
> 13 years 43 (10.5%) 61 (7.5%) 4.25 2.68–6.72 < 0.001
Sex n = 817 0.732
Female 200 (48.9%) 408 (49.9%) Base
Male 209 (51.1%) 409 (50.1%) 1.04 0.82–1.32 0.732
Neuter status n = 817 0.001
Entire 120 (29.3%) 322 (39.4%) Base
Neutered 289 (70.7%) 495 (60.6%) 1.57 1.21–2.02 0.001
Sex-neuter n = 817 < 0.001
Male-entire 49 (12.0%) 173 (21.2%) Base
Male-neutered 160 (39.1%) 236 (28.9%) 2.39 1.64–3.48 < 0.001
Female-entire 78 (19.1%) 149 (18.2%) 1.85 1.22–2.81 0.004
Female-neutered 122 (29.8%) 259 (31.7%) 1.66 1.13–2.44 0.009
Weight: PUREBRED ONLY n = 253 n = 485 < 0.001
Below breed mean 92 (36.4%) 246 (50.7%) Base
At or above breed mean 161 (63.6%) 239 (49.3%) 1.80 1.32–2.46 < 0.001
Purebred status 0.051
Crossbred 92 (22.5%) 226 (27.7%) Base
Purebred 317 (77.5%) 591 (72.3%) 1.15 1.00–1.32 0.051
Breed ≥ 10 dogs and/or ≥ 5 case dogs < 0.001
Crossbred 88 (21.5%) 204 (24.9%) Base
Tibetan Terrier 9 (2.2%) 2 (0.2%) 10.43 2.21–49.27 0.003
Border Terrier 21 (5.1%) 10 (1.2%) 4.87 2.20–10.76 < 0.001
Cairn Terrier 5 (1.2%) 3 (0.4%) 3.86 0.90–16.52 0.068
Miniature Schnauzer 10 (2.4%) 6 (0.7%) 3.86 1.36–10.96 0.011
West Highland White Terrier 53 (13.0%) 32 (3.9%) 3.84 2.32–6.36 < 0.001
Yorkshire Terrier 30 (7.3%) 23 (2.8%) 3.02 1.66–5.50 < 0.001
Bichon Frise 11 (2.7%) 15 (1.8%) 1.70 0.75–3.85 0.203
Cavalier King Charles Spaniel 16 (3.9%) 22 (2.7%) 1.69 0.84–3.36 0.138
Jack Russell Terrier 32 (7.8%) 51 (6.2%) 1.45 0.88–2.42 0.148
Border Collie 13 (3.2%) 23 (2.8%) 1.31 0.63–2.70 0.465
Cocker Spaniel 13 (3.2%) 26 (3.2%) 1.16 0.57–2.36 0.684
Purebred (other) 71 (17.4%) 269 (32.9%) 0.90 0.61–1.33 0.597
Labrador Retriever 25 (6.1%) 76 (9.3%) 0.76 0.45–1.28 0.304
Lhasa Apso 4 (1.0%) 13 (1.6%) 0.71 0.23–2.25 0.564
Staffordshire Bull Terrier 12 (2.9%) 56 (6.9%) 0.50 0.25–0.97 0.041
Springer Spaniel – unspecified 2 (0.5%) 12 (1.5%) 0.39 0.08–1.76 0.219
Golden Retriever 1 (0.2%) 9 (1.1%) 0.26 0.03–2.06 0.201
Boxer 1 (0.2%) 11 (1.35) 0.21 0.03–1.66 0.139
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associations with survival, and was therefore included.
Inspection of the Nelson-Aalen cumulative hazard plots
and Schoenfeld residuals (P = 0.113) suggested the pro-
portional hazards assumption was not violated.
Discussion
This is the largest study to date exploring risk factors for
DM in dogs in primary-care practices. It is the first to
look at data from across the whole of the UK, and to ex-
plore associations between initial management methods
for DM and survival. Dogs > 8 years of age, female entire
dogs, male neutered dogs, WHWT and Border Terrier
breeds in particular, dogs documented as obese, or hav-
ing a concurrent diagnosis of hyperadrenocorticism or
pancreatitis were all associated with an increased odds
of DM diagnosis. Variables associated with an increased
hazard of death after diagnosis included dogs that were ≥
10 years of age at diagnosis, entire, previously on gluco-
corticoids, having had a BG level > 40 mmol/L at diagno-
sis, or dogs that did not start insulin treatment.
The prevalence of DM in the current study (0.26%)
was calculated for dogs aged 3 years or above, and there-
fore may not be directly comparable to the higher preva-
lence values of 0.32–0.36% reported by other UK and
Australian studies assessing the overall population dogs
within a primary-care setting [1–3]. However the current
study may offer a more accurate representation of the
wider UK dog population, as previous studies were lim-
ited to only insured dogs [1], or only data from England
[2]. Similarly, prevalence estimates of 0.64–1.33% re-
ported by studies of hospital-based populations [11, 36]
are likely to be biased due to the referred source popula-
tion [37], and may not accurately reflect the wider dog
population. In the current study, only 5.9% (24/409) of
incident cases were referred for advanced management,
highlighting the importance of studies from primary-
care practice given that referral centres may be missing
almost 95% of DM cases from the general dog
population.
The annual incidence risk in dogs aged ≥3 years in the
current study was estimated at 0.09% (95% CI: 0.08–
Table 2 Descriptive and univariable logistic regression results (Continued)
Variable Case (%) n = 409 Control (%) n = 818 Odds Ratio 95% CIa Category
P-value
Variable
P-value
Shih-Tzu 2 (0.5%) 24 (2.9%) 0.19 0.04–0.84 0.028
Chihuahua 1 (0.2%) 14 (1.7%) 0.17 0.02–1.28 0.085
German Shepherd Dog 1 (0.2%) 14 (1.7%) 0.17 0.02–1.28 0.085
English Springer Spaniel 0 (0.0%) 10 (1.2%) . . .
Pug 0 (0.0%) 10 (1.2%) . . .
Co-morbidities/medication
Glucocorticoids: Yes 34 (8.3%) 28 (3.4%) 2.56 1.53–4.28 < 0.001 < 0.001
No 375 (91.7%) 790 (96.6%) Base
Obesity: Yes 67 (16.4%) 79 (9.7%) 1.83 1.29–2.60 0.001 0.001
No 342 (83.6%) 739 (90.3%) Base
Hyperadrenocorticism: Yes 26 (6.4%) 2 (0.2%) 27.7 6.54–117.29 < 0.001 < 0.001
No 383 (93.6%) 816 (99.8%) Base
Pancreatitis: Yes 46 (11.3%) 1 (0.1%) 103.53 14.22–753.62 < 0.001 < 0.001
No 363 (88.8%) 817 (99.9%) Base
Insurance status n = 817 < 0.001
Insured 133 (32.5%) 113 (13.8%) 3.00 2.25–4.00 < 0.001
Not Insured 276 (67.5%) 704 (86.2%) Base
Veterinary group < 0.001
A 3 (0.7%) 3 (0.4%) 0.82 0.16–4.10 0.805
B 147 (35.9%) 244 (29.9%) 0.49 0.37–0.66 < 0.001
C 55 (13.5%) 40 (4.9%) 1.12 0.71–1.77 0.621
D 201 (49.1%) 164 (20.1%) Base
E 3 (0.7%) 366 (44.8%) 0.01 0.002–0.02 < 0.001
Descriptive statistics and univariable logistic regression for variables associated with diabetes mellitus in dogs aged 3 years and older attending UK primary-care
practices in 2016.
a Confidence Interval
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Table 3 Multivariable logistic regression results
Variable Odds Ratio 95% CIa Category P-value Variable
P-value
Age at diagnosis < 0.001
3 to < 8 years Base
8 to < 10 years 4.04 2.63–6.23 < 0.001
10 to < 13 years 7.18 4.60–11.20 < 0.001
> 13 years 3.55 1.97–6.40 < 0.001
Sex-neuter < 0.001
Male-entire Base
Male-neutered 1.99 1.18–3.34 0.010
Female-entire 3.03 1.69–5.44 < 0.001
Female-neutered 1.36 0.80–2.31 0.250
Breed ≥ 10 dogs and/or ≥ 5 case dogs < 0.001
Tibetan Terrier 8.48 0.94–76.76 0.057
Miniature Schnauzer 4.09 0.90–18.55 0.068
Border Terrier 3.37 1.04–10.98 0.043
West Highland White Terrier 2.88 1.49–5.56 0.002
Cavalier King Charles Spaniel 2.43 0.95–6.20 0.064
Cairn Terrier 2.25 0.38–13.38 0.372
Yorkshire Terrier 2.09 0.93–4.69 0.073
Border Collie 1.57 0.58–4.27 0.378
Bichon Frise 1.47 0.40–5.41 0.559
Springer Spaniel – unspecified 1.20 0.15–9.70 0.864
Cocker Spaniel 1.13 0.48–2.66 0.782
Jack Russell Terrier 1.04 0.54–1.98 0.913
Crossbred Base
Purebred (other) 0.87 0.52–1.44 0.589
Labrador Retriever 0.83 0.43–1.57 0.559
Lhasa Apso 0.65 0.11–3.73 0.624
Staffordshire Bull Terrier 0.42 0.18–0.98 0.046
Boxer 0.21 0.02–2.18 0.193
Chihuahua 0.20 0.02–2.09 0.177
Shih-tzu 0.20 0.04–0.96 0.045
Golden Retriever 0.17 0.02–1.75 0.137
German Shepherd Dog 0.08 0.01–0.74 0.025
English Springer Spaniel . . .
Pug . . .
Concurrent conditions/medication:
Glucocorticoid treatment: Yes 2.19 1.02–4.70 0.044 0.044
No Base
Obesity mentioned 1 yr prior to diagnosis: Yes 2.71 1.63–4.52 < 0.001 < 0.001
No Base
Hyperadrenocorticism +/− 3 months diagnosis: Yes 11.28 2.41–52.73 0.002 0.002
No Base
Pancreatitis +/− 3 months diagnosis: Yes 1085.19 36.36–32,390.61 < 0.001 < 0.001
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0.09%). The study by Fall et al. (2007) on a Swedish in-
sured dog population reported the cumulative propor-
tion of dogs developing DM by 12 years of age as 1.2%,
approximating to an annual incidence risk of 0.1% [38].
It is very difficult to compare these two studies due to
the different source populations and methodologies for
calculating annual incidence risk. Human T1DM had a
reported average annual increase of 2.8% worldwide be-
tween 1990 and 1999 [10], and previous studies have
suggested that the incidence of canine DM may also be
increasing [11, 12].
Diagnostic testing information was available for 95.8%
(392/409) DM cases in the current study. Of these dogs
32.8% (134) were ketotic at diagnosis which, having been
assessed via urinary dipsticks, is likely to be an under-
estimate because this test will not detect all types of
ketone bodies [39]. This relatively high prevalence of ke-
tosis at the time of diagnosis in primary care practice
has not previously been reported. The same percentage
of dogs (32.8%, 134) either presented with or developed
cataracts within 3 months of DM diagnosis. The current
study did not discriminate between diabetic and non-
diabetic cataracts. However, some cases that developed
cataracts may not have been documented in the clinical
notes, suggesting that this figure could be an underesti-
mate. Previous studies have reported 50% of diabetic
Table 3 Multivariable logistic regression results (Continued)
Variable Odds Ratio 95% CIa Category P-value Variable
P-value
No Base
Veterinary group < 0.001
A 1.06 0.16–7.11 0.955
B 0.58 0.41–0.83 0.003
C 1.14 0.66–1.99 0.631
D Base
E 0.003 0.0004–0.02 < 0.001
Multivariable logistic regression for risk factors associated with diabetes mellitus in dogs 3 years and older attending UK primary-care practices in 2016, n = 1205.
a Confidence Interval
Table 4 Euthanasia reasons for dogs diagnosed with diabetes mellitus
Reasons for euthanasia (multiple allowed): Number of cases (%)
n = 233
Condition worsening 136 (58.4%)
Owner not coping with condition 15 (6.4%)
Financial 25 (10.7%)
Contributary conditions 133 (57.1%)
No reason given 44 (18.9%)
Contributory conditions listed as (multiple allowed)
Ocular disorder all 33 (14.2%)
cataracts/ blindness 26 (11.2%)
Pancreatitis 17 (7.3%)
Neoplasia 17 (7.3%)
Poor quality of life/deterioration – unspecific 17 (7.3%)
Kidney disease 13 (5.6%)
Neurological condition all 12 (5.2%)
seizures 7 (3.0%)
Liver disease 10 (4.3%)
Diabetic ketoacidosis 8 (3.4%)
Hyperadrenocorticism 7 (3.0%)
Blood disorder 5 (2.1%)
Temperament of the dog 2 (0.9%)
Euthanasia reasons for dogs aged 3 years and older diagnosed with diabetes mellitus attending UK primary-care practices in 2016, n = 233.
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Table 5 Univariable cox regression results
Variable Number (%) n = 409 Hazard Ratio 95% CIa Category
P-value
Variable
P-value
Age at diagnosis Median (range) 10.00 (3.16–18.00) < 0.001
Age at diagnosis
3 to < 8 years 77 (18.8%) Base < 0.001
8 to < 10 years 124 (30.3%) 1.05 0.70–1.59 0.805
10 to < 13 years 165 (40.3%) 2.25 1.54–3.29 < 0.001
> 13 years 43 (10.5%) 2.69 1.64–4.43 < 0.001
Sex 0.277
Female 200 (48.9%) Base
Male 209 (51.1%) 0.87 0.68–1.12 0.277
Neuter status 0.001
Entire 120 (29.3%) Base
Neutered 289 (70.7%) 0.62 0.47–0.81 0.001
Sex-neuter 0.072
Male-entire 49 (12.0%) Base
Male-neutered 160 (39.1%) 0.63 0.42–0.95 0.029
Female-entire 78 (19.1%) 0.92 0.58–1.47 0.738
Female-neutered 122 (29.8%) 0.74 0.48–1.12 0.155
Purebred status
Crossbred 92 (22.5%) Base 0.895
Purebred 317 (77.5%) 0.99 0.86–1.15 0.895
Weight: PUREBRED ONLY n = 253
Below breed mean 92 (36.4%) Base 0.459
At or above breed mean 161 (63.6%) 0.88 0.63–1.23 0.459
Breed (≥5 dogs per breed)
Crossbred 88 (21.5%) Base 0.029
Staffordshire Bull Terrier 9 (2.2%) 2.16 1.02–4.55 0.043
Cocker Spaniel 21 (5.1%) 1.61 0.85–3.07 0.147
Border Terrier 5 (1.2%) 1.40 0.80–2.43 0.239
Jack Russell Terrier 10 (2.4%) 1.20 0.72–1.99 0.487
Purebred (other) 53 (13.0%) 1.11 0.73–1.67 0.631
Labrador Retriever 30 (7.3%) 1.16 0.67–1.99 0.599
Tibetan Terrier 11 (2.7%) 0.81 0.33–2.02 0.653
West Highland White Terrier 16 (3.9%) 1.07 0.70–1.64 0.753
Cavalier King Charles Spaniel 32 (7.8%) 0.67 0.32–1.41 0.291
Miniature Schnauzer 13 (3.2%) 0.82 0.35–1.89 0.636
Yorkshire Terrier 13 (3.2%) 0.63 0.36–1.09 0.097
Cairn Terrier 25 (6.1%) 0.46 0.11–1.89 0.281
Border Collie 71 (17.4%) 0.47 0.21–1.03 0.060
Bichon Frise 12 (2.9%) 0.43 0.17–1.07 0.069
Co-morbidities/medication:
Glucocorticoids Yes 34 (8.3%) 1.70 1.14–2.52 0.014
No 375 (91.7%) Base 0.014
Obesity Yes 67 (16.4%) 0.67 0.47–0.96 0.023
Heeley et al. Canine Medicine and Genetics             (2020) 7:6 Page 10 of 19
Table 5 Univariable cox regression results (Continued)
Variable Number (%) n = 409 Hazard Ratio 95% CIa Category
P-value
Variable
P-value
No 342 (83.6%) Base 0.023
Hyperadrenocorticism Yes 26 (6.4%) 1.33 0.82–2.15 0.263
No 383 (93.6%) Base 0.263
Pancreatitis Yes 46 (11.3%) 1.11 0.76–1.61 0.593
No 363 (88.8%) Base 0.593
Insurance status
Insured 133 (32.5%) 0.86 0.67–1.12 0.267
Not Insured 276 (67.5%) Base 0.267
Veterinary group 0.8437
A 3 (0.7%) 1.08 0.15–7.71 0.941
B 147 (35.9%) 0.89 0.67–1.18 0.403
C 55 (13.5%) 1.12 0.77–1.63 0.549
D 201 (49.1%) Base
E 3 (0.7%) 1.09 0.27–4.41 0.903
BG level at diagnosis 0.003
Median (range) mmol/L 28.1 (12.2–51.7)
< 20 mmol/L 34 (8.3%) Base
20 to < 30mmol/L 108 (26.4%) 0.93 0.55–1.57 0.774
30 to < 40mmol/L 83 (20.3%) 1.53 0.90–2.61 0.118
> 40 mmol/L 23 (5.6%) 2.48 1.29–4.78 0.007
No evidence/record of BG level 161 (39.4%) 1.37 0.83–2.27 0.215
Ketotic at diagnosis 0.095
Ketotic 134 (32.8%) 1.15 0.86–1.54 0.332
Not ketotic 179 (43.8%) Base
No record of assessing ketones 96 (23.5%) 1.42 1.04–1.95 0.028
Cataracts diagnosed within 3months of diagnosis 0.500
Cataracts diagnosed 134 (32.8%) 0.91 0.70–1.19 0.502
No mention of cataracts 275 (67.2%) Base
Hospitalised at diagnosis 0.866
Dog hospitalised 66 (16.1%) 0.97 0.69–1.36 0.867
No evidence of hospitalisation 343 (83.9%) Base
Referred for advanced management 0.991
Referred 24 (6.0%) 1.00 0.57–1.75 0.991
Not referred 378 (94.0%) Base
Insulin treatment < 0.001
Treated with insulin 362 (88.5%) 0.08 0.05–0.12 < 0.001
Not treated 40 (9.8%) Base
Insulin treatment unknown 7 (1.7%) . . .
Initial insulin regime n = 328 0.883
Once daily injections 67 (20.4%) 0.91 0.62–1.32 0.612
Twice daily injections 224 (68.3%) Base
> 2x daily injections 24 (7.3%) 1.17 0.68–2.03 0.571
Constant Rate Infusion 13 (4.0%) 0.96 0.45–2.06 0.921
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dogs developing cataracts within 6 months [40, 41]. Al-
though diabetic cataracts can be managed surgically, this
is not always affordable for owners and ocular health
was cited as a contributory reason for euthanasia in
14.2% (33/233) of all euthanasia decisions.
Age was strongly associated with the odds of diagnosis of
DM. Consistent with other studies [2, 11], dogs over 8 years
were at increased risk, with those aged 10 to < 13 years hav-
ing over 7 times the odds of DM diagnosis compared to
dogs aged 3 - < 8 years. No association was detected with
sex, which is consistent with other studies [2, 14]. However,
there was a strong association with the combined sex-
neuter variable. Similar to previous findings, neutered males
had almost twice the odds [2, 3, 11], and entire females had
three times the odds of developing DM compared to entire
males. Where there is a large entire female population, such
as in Sweden, the increase in female cases of DM is thought
to be a reflection of dioestrus diabetes [16]. However, des-
pite the evidence between hormonal changes in dioestrus
and the development of diabetes [20, 26, 42], overall the
current study found no significant difference between entire
and neutered females in developing DM. Instead, it sug-
gests that entire males may be “protected”. Cross-sectional
studies in humans have reported that men with lower tes-
tosterone levels have an increased T2DM risk [43]. In spon-
taneous mouse models of T1DM, such as the non-obese
diabetic mouse, females are predisposed to diabetes, an ef-
fect thought to be mediated through testosterone-driven ef-
fects on the microbiome [44]. Although the pathogenesis of
DM in dogs is heterogeneous, one mechanism by which
male entire dogs may be relatively protected is via increased
testosterone. However, this hypothesis may only be relevant
to a proportion of diabetes cases, and was not investigated
directly in the present study.
Breed associations were consistent with previous find-
ings [3, 13, 15, 16], and add weight to the evidence that
DM has a genetic component [7, 13]. To identify new
genes and potential treatment targets in canine diabetes,
understanding which breeds are genetically protected
from DM is just as important as identifying those with a
predisposition. In an aim to explore the effect of breed
on both predisposition and protection in the current
study, breeds with ≥10 dogs within cases and controls
combined, and/or breeds with ≥5 DM cases were in-
cluded as individual breeds within the ‘breed’ variable.
Other breeds falling outside this definition were com-
bined as ‘purebred other’. This enabled these individ-
ual breeds to be evaluated within the multivariable
logistic analysis, and after adjustment for other vari-
ables and confounders on breed, aiming to provide a
more accurate understanding of associations com-
pared to most previous studies that use univariable
analysis only. However, despite 1205 dogs being
taken forward to multivariable analysis, this categor-
isation was still under-powered to evaluate breeds
adequately where there were very few or no cases,
despite the breed itself being relatively common. In
this respect, this study was unable to identify all
Table 5 Univariable cox regression results (Continued)
Variable Number (%) n = 409 Hazard Ratio 95% CIa Category
P-value
Variable
P-value
MANAGEMENT (multiple methods per dog)
Home blood glucose measurements: Yes 45 (11.0%) 1.06 0.74–1.52 0.733 0.735
No 338 (89.0%) Base
Blood glucose curve practice: Yes 234 (57.2%) 0.51 0.39–0.65 < 0.001 < 0.001
No 175 (42.8%) Base
Fructosamine: Yes 135 (33.0%) 0.65 0.50–0.85 0.001 0.001
No 274 (67.0%) Base
Spot blood glucose: Yes 247 (60.4%) 0.66 0.51–0.85 0.001 0.001
No 162 (39.6%) Base
Bloods (unspecified): Yes 110 (26.9%) 0.82 0.62–1.09 0.171 0.164
No 299 (73.1%) Base
Urinalysis: Yes 160 (39.1%) 0.79 0.61–1.01 0.063 0.061
No 249 (60.9%) Base
Recommended diet change: Yes 149 (36.4%) 0.53 0.41–0.70 < 0.001 < 0.001
No 260 (63.6%) Base
Other (Fluid therapy/imaging): Yes 108 (26.4%) 1.07 0.81–1.41 0.632 0.632
No 301 (73.6%) Base
Univariable cox regression survival analysis for dogs 3 years and older, diagnosed with diabetes mellitus at UK primary-care practices in 2016.
a Confidence Interval
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breeds at high risk of developing DM, and the find-
ings focus on the breeds that were commonly repre-
sented in the UK during 2016.
The current study identified that WHWTs and Border
Terriers were “at risk”, having approximately 3 times the
odds of DM compared to crossbreds. Samoyeds are
Table 6 Multivariable cox regression results
Variable Hazard Ratio
(n = 409)
95% CIa Category P-value Variable P-value
Age at diagnosis < 0.001
3 to < 8 years Base
8 to < 10 years 0.98 0.64–1.50 0.935
10 to < 13 years 2.12 1.42–3.18 < 0.001
> 13 years 2.02 1.17–3.49 0.011
Neuter status < 0.001
Entire Base
Neutered 0.56 0.42–0.78 < 0.001
Breed ≥ 5 dogs 0.050
Cocker Spaniel 2.06 1.06–4.01 0.034
Staffordshire Bull Terrier 1.85 0.86–3.97 0.116
Border Terrier 1.19 0.68–2.10 0.543
Labrador Retriever 1.08 0.62–1.89 0.786
Purebred (other) 1.00 0.63–1.57 0.989
Crossbred Base
Miniature Schnauzer 0.96 0.41–2.25 0.925
Jack Russell Terrier 0.88 0.51–1.52 0.655
Cavalier King Charles Spaniel 0.86 0.40–1.84 0.690
Tibetan Terrier 0.72 0.28–1.84 0.489
Yorkshire Terrier 0.69 0.39–1.21 0.198
West Highland White Terrier 0.69 0.44–1.08 0.103
Cairn Terrier 0.56 0.13–2.37 0.432
Bichon Frise 0.46 0.18–1.16 0.101
Border Collie 0.39 0.17–0.87 0.022
BG level at diagnosis 0.004
< 20 mmol/L Base
20 to < 30 mmol/L 0.96 0.55–1.70 0.913
30 to < 40 mmol/L 1.52 0.88–2.65 0.137
> 40 mmol/L 2.75 1.35–5.57 0.005
No evidence/record of BG test 1.42 0.84–2.41 0.187
Insulin treatment < 0.001
Insulin treatment started 0.08 0.05–0.12 < 0.001
No insulin treatment Base
Insulin treatment unknown . . .
Glucocorticoid treatment 6 wks prior to diagnosis 0.008
Yes 1.83 1.20–2.80 0.005
No Base
Veterinary group 0.087
A 2.12 0.26–17.38 0.488
B 0.75 0.56–1.02 0.063
C 1.35 0.91–2.02 0.137
D Base
E 1.64 0.39–6.99 0.501
Multivariable cox regression survival analysis for dogs 3 years and older diagnosed with diabetes mellitus at UK primary-care practices in 2016.
a Confidence Interval
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frequently over-represented in DM cases in other studies
and although there was only one Samoyed present in
this case control study, it was a DM case. Breeds with
reduced odds of DM compared to crossbreds included
GSD and Shih-Tzu, as well as SBT, a breed consistent
with suggestive findings in other studies [2], but not pre-
viously significantly associated with lower DM risk.
Interestingly the current study contained 10 English
Springer Spaniels and 10 Pugs, but there were no cases
documented for either of these breeds. Pugs have not
previously been associated with a decreased odds of DM,
whereas English Springer Spaniels have been associated
with both a reduced odds of DM in the UK [13], and an
increased odds of DM in Australia [3]. This suggests that
different genetic subpopulations of English Springer Span-
iels with different susceptibilities to DM may exist across
these two geographical regions. This may be a useful area
for further research into the genetics of DM in dogs.
Dogs documented as obese were associated with 2.7
times the odds of DM diagnosis (95% CI 1.63–4.52, p <
0.001). Despite no clear biological reason for obese dogs
to be prone to DM due to insulin deficiency [24], this
finding adds to evidence from other studies that obesity
may be a risk factor for the disorder [2, 26], potentially
by causing insulin resistance. The present study relied
on subjective, unprompted recording of obesity by the
veterinary professional, therefore under-reporting was
likely, particularly with regards to controls, because cases
had more detailed histories/examinations. Diet has also
been associated with DM in dogs [26], and because
obesity is often associated with poor dietary control and
limited exercise [45], another explanation is that “obes-
ity” may be acting as a proxy for other associated risk
factors. It is clear that more research is required to es-
tablish the exact link between obesity in dogs and DM.
Interestingly obesity was not associated with, nor con-
founded by, prior glucocorticoid treatment. The latter
was associated with roughly double the odds of DM,
which is likely to reflect insulin resistance caused by
these drugs [46].
Concurrent hyperadrenocorticism and pancreatitis
were both strongly associated with DM diagnosis, con-
sistent with several other studies [2, 3, 17, 27]. The re-
sults should be interpreted with some caution because
the numbers of controls with these conditions in this
study were low, albeit consistent with the prevalence of
these diseases (approx. 0.02–0.04%) in the wider UK dog
population [47]. The temporality, and causation, be-
tween pancreatitis and DM is also difficult to determine
[32], and interestingly only 13% (6/46) of the pancreatitis
diagnoses in the current study clearly preceded DM. In
total pancreatitis was documented in an unprompted
way in 11.3% of cases, similar to the 11.5% reported in a
previous UK primary-care study [2], but less than the
17.7% reported in DM cases in primary-care practice in
Australia [3], and the 19% reported by an Italian referral
study [34]. It is likely that pancreatitis is under-reported
in the current study for both cases and controls due to
non-specific clinical signs, and lack of definitive diagnos-
tics being performed. Further research is required to fully
understand the interplay between these two diseases.
Where recorded, the most common management
methods for DM in the first 3 months were home or
practice BG curves (70.6%, 255/361), followed by spot
BG measurements (68.4%, 247), even though the latter is
considered unreliable for monitoring [48]. Only 4.2%
[15] of dogs were managed by spot BG alone, suggesting
this method is primarily used as an augmentation to
other management techniques.. Identification of man-
agement techniques and diagnostics currently employed
by primary-care clinicians by this study provides a
benchmark against which individuals and clinics can
compare their own processes and practices.
Median survival time for all dogs with DM was 15.6
months (95% CI: 10.4–20.0months). This estimate is
likely to be negatively skewed by inclusion of dogs where
DM management was not realistically attempted. To ac-
count for this, an MST was calculated for all dogs surviv-
ing at least 7 days post diagnosis, estimated at 20.2months
(95% CI: 16.6–24.7months). The all dogs MST estimated
in this study is consistent with the 17.3months reported
by an earlier VetCompass study [2], but differs substan-
tially from the reported MST of 2months from a popula-
tion of insured Swedish dogs [16], and of 32months for
dogs presenting to a referral hospital in Italy [34]. This
may reflect differences between countries, or that dogs
presenting to a referral hospital are more likely to have
motivated owners and access to gold standard level of
care. Successful treatment of DM requires substantial
owner commitment, and given that 92.5% of the dogs in
the current study died due to an owner’s decision to eu-
thanise, it is clear that MST is strongly influenced by a
variety of owner-related factors such as their finances, life-
style or perception of the condition.
Age at diagnosis, neuter status and breed have all previ-
ously been associated with DM survival [2, 16], and were
also associated in the current study. Dogs aged ≥10 years
and Cocker Spaniels had twice the hazard of death com-
pared to dogs 3 to < 8 years and crossbreds respectively.
Conversely, Border Collies and neutered animals had a
lower hazard compared to crossbreds and entire animals.
The differences in survival between breeds may reflect
genetic differences involved in the pathogenesis of the dis-
ease. Interestingly previously studies have found a female
predisposition to DM in Border Collies [13, 16], suggest-
ing dioestrus diabetes may be more prevalent in this
breed. In the current study 92.3% (12/13) of the Border
Collie cases were females, with 6 of these were entire and
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6 were neutered at the time of diagnosis. The increased
survival found in this breed could therefore be partially re-
lated to survival associated with dioestrus diabetes cases,
where remission may be possible following ovariohyster-
ectomy. Whilst the clinical signs associated with canine
DM, such as polyuria and polydipsia are relatively consist-
ent, the underlying pathogenesis is relatively heterogeneous.
More detailed and consistent clinical phenotyping at the
time of diagnosis e.g. measurement of pancreatic inflamma-
tory markers, would enable improved disease classification,
allowing further insights to be gained into the relationship
between underlying pathogenesis and survival.
Overall, neutered animals had a lower hazard of death
once diagnosed (hazard ratio (HR): 0.56, 95% CI 0.42–
0.78, p < 0.001) which is consistent with the findings of a
previous UK primary-care study [2]. There is no clear
reason whether this is biological or due to neutering act-
ing as a proxy for some other measure such as the
owner’s ability and willingness to treat DM.
Insurance status and concurrent pancreatitis have previ-
ously been associated with survival in primary-care prac-
tice [2]. Pancreatitis was cited as a cause of death in 7.3%
(17/233) of euthanised cases, but in the current study did
not identify an association between survival with insur-
ance status, or the diagnosis of concurrent pancreatitis or
hyperadrenocorticism at the time of DM diagnosis. A re-
cent referral study similarly did not identify association
with pancreatitis and survival [34], suggesting that pan-
creatitis, where recognised in the 3months before or after
diagnosis, may not significantly affect survival.
Other variables associated with survival in the current
study included BG level at diagnosis, insulin treatment,
and glucocorticoid treatment. Dogs with a BG reading >
40mmol/L at diagnosis had a hazard ratio of 2.75 (95%
CI: 1.35–5.57, p = 0.004) compared to dogs with a BG
reading < 20 mmol/L. Higher BG levels at diagnosis may
reflect “sicker” dogs or those in diabetic ketoacidosis, yet
neither hospitalisation, or being ketotic at diagnosis, (a
proxy measure for diabetic ketoacidosis) were associated
with BG levels or survival. A referral study of incident
cases reported that BG levels in untreated dogs were not
associated with survival in multivariable analysis [34].
Although this was a smaller study and limited to a refer-
ral caseload, these differing findings to the current study
may reflect intrinsic differences between typical treat-
ment options and survival in a referral versus primary-
care setting. In primary-care practice, early identification
of DM, before BG levels rise > 40 mmol/L, may be im-
portant for this population of dogs to have a better
chance of stabilisation and survival. Dogs starting insulin
had a significantly reduced hazard of death (HR: 0.08,
95% CI 0.05–0.12, p < 0.001), consistent with the fact
that virtually all dogs are insulin dependent by the time
of diagnosis [9]. There was evidence from the current
study that previous glucocorticoid treatment increased
the hazard of death (HR: 1.83, 95% CI 1.20–2.80, p =
0.005). This may result from increased difficulties in
managing DM concurrently with other disorders that re-
quire glucocorticoid treatment.
The presence of ketotis at diagnosis was not adversely
associated with survival, and diabetic ketoacidosis was
mentioned as a reason for euthanasia in only 3.4% of
cases. Despite diabetic ketoacidosis potentially being a
life-threatening condition, it appears not to be a driving
factor for survival. This may reflect the confidence of
primary practitioners in attempting treatment of the
condition, rather than opting for euthanasia, or an
under-reporting of the condition. The latter is likely to
be true in this study where urine strips to identify ke-
tones were used as a proxy for diabetic ketoacidosis at
diagnosis, and where further investigations to diagnose
diabetic ketoacidosis at the point of euthanasia was often
not undertaken or reported in the clinical notes.
The study included information on a variety of man-
agement methods that were used to manage/monitor
DM during the first 3 months following diagnosis, in-
cluding BG curves at the practice, recommended diet
change, spot BG and fructosamine measurements. At a
univariable level, several of these methods were associ-
ated with increased survival. However, because these
management methods were highly correlated with each
other, and with insulin treatment, it was inappropriate
to retain them all in the final model. Insulin treatment
was retained as this had the greatest impact on the HR.
Because dogs that survived longer had a longer duration
of exposure to the chance of receiving management
methods, it was aimed to minimise this survival-bias ef-
fect by restricting observations on management to the
first 3 months post diagnosis. As many of the manage-
ment methods were associated with increased survival, it
can be argued that contact with the practice within these
first few months is more important for survival than the
type of management technique per se. This contact is
likely to be a proxy for owner commitment and compli-
ance, as well as the availability of support from the prac-
tice, and it has been argued that assessment of these on
long term survival is more important than considering
specific patient characteristics [49]. Further studies into
survival of DM cases should consider ways to capture
this element of owner compliance.
There were a number of limitations to this study. As it
relied on reviewing of retrospective Electronic Patient
Records (EPRs), inconsistencies and inaccuracies within
these may have led to either missing data, or misclassifi-
cation for variables such as obesity/medications/concur-
rent conditions. Errors relating to these inconsistencies
were more likely to occur with controls than cases be-
cause the latter group were more likely to have higher
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counts of veterinary visits and investigations for concur-
rent conditions. The number of dogs within each breed
category was dependant on the popularity of that breed
within the UK within 2016. This meant there was insuffi-
cient power to detect potentially significant differences
within breeds where there were low numbers, for example
the inability of this study to detect Samoyeds as high risk
for developing DM. Additionally, although misclassifica-
tion of DM was thought unlikely because this is a routine
primary-care veterinary diagnosis, a veterinary diagnosis
of pancreatitis or hyperadrenocorticism in DM cases may
have been misclassified due to similarities in clinical signs
or difficulties in interpreting diagnostic tests.
Conclusions
Middle-aged dogs, neutered males, specific breeds, gluco-
corticoid treatment and concurrent hyperadrenocorticism
or pancreatitis were all associated with DM diagnosis in
dogs. Additionally, there is an indication for further ex-
ploration of the associations between DM and obesity.
Survival with DM is associated with age, breed and neu-
tering. Survival was also associated with insulin treatment
and BG level at diagnosis, suggesting early identification
and treatment of DM patients in primary-care practice
can help increase survival times. Awareness of these fac-
tors can aid veterinary professionals in the management
and advice on prognosis after diagnosis of DM in dogs.
Methods
Study design and period
This study aimed to estimate prevalence and incidence,
and investigate risk factors for DM and the survival of
DM cases in dogs. This study used data from Electronic
Patient Records (EPRs) of dogs attending UK primary-
care veterinary practices collaborating within the Vet-
Compass Programme. The study population consisted of
the cohort of all dogs ≥3 years on the 1st January 2016
that were under the care of a VetCompass practice as
evidenced by having an EPR during 2016, or in both
2015 and 2017. This study population was restricted to
dogs ≥3 years for both cases and controls in order to ex-
clude the less typical juvenile-onset DM cases which are
likely to differ in their DM aetiology.
A nested case-control study was used to investigate
risk factors for the diagnosis of DM, and the underlying
study cohort was used to estimate prevalence, incidence
and to examine survival post diagnosis. Sample size cal-
culations estimated an unmatched case-control study
would require approximately 350 cases and 700 controls
to detect an odds ratio (OR) of at least 2.0 where at least
5% of the controls were exposed to the risk factor of
interest (95% confidence level, 80% power, 1:2 case:con-
trol ratio) (OpenEpi v.3.012013). Ethical approval was
granted by Royal Veterinary College Clinical Research
Ethical Review Board (reference: SR2018–1652).
Data collection and management
Potential DM cases were identified by searching the
EPRs for terms related to diabetes diagnosis/manage-
ment within the free text clinical records (diab, insul,
hyperg, mell, glucose, DM, ketoa, ketou, IDDM, fruct,
curve, insuv, prozi, canins, vetp, vet pen), treatment re-
cords (canins, insul, prozi, neutral, lent, vetp, vet pen,
insuv), and recorded VeNom diagnosis fields (Diabetes
mellitus, Diabetes mellitus – unstable, Diabetes mellitus
– stable, Diabetic ketoacidosis). The EPRs were exam-
ined manually to identify cases, and their date of diagno-
sis. A DM case was defined as a final veterinary
diagnosis of DM, treatment with insulin, or strong evi-
dence of a veterinary diagnosis based on evidence of
hyperglycaemia, glucosuria and appropriate clinical signs
in the EPR. The date of diagnosis was the earliest date of
either veterinary confirmation of diagnosis, receipt of
confirmatory test results, or initiation of insulin treat-
ment. Dogs treated with insulin for hyperkalaemia
without hyperglycaemia were excluded. Cases that were
pre-existing or newly diagnosed during 2016 were used
to estimate a one-year period prevalence. Only cases
newly diagnosed during 2016 were retained for estima-
tion of incidence and for the risk factor and survival
analysis.
Case-control study
For each case, there were two control dogs randomly se-
lected from the study population aged ≥3 years on 01/
01/2016. Controls were excluded if the dog had pre-
existing DM, developed DM prior to July 2019, or if the
VetCompass record did not include evidence of direct
owner/patient contact with the practice. To establish an
equivalent to “date of diagnosis” for the controls, a ran-
dom date in 2016 was generated for each dog and the
nearest VetCompass record to this date was used to de-
termine time-bound exposure variables.
Case and control demographic data extracted from
VetCompass included: breed, date of birth, sex, neuter-
ing status, bodyweight, insurance status and veterinary
group. Sex and neuter status were examined individually
and also combined as a sex-neuter variable. Breeds were
categorised as purebred or crossbred. Purebreds were
further classified using the VeNom breed terms and ana-
lysed individually if they included ≥10 dogs and/or ≥ 5
DM cases in the overall case-control study. All purebred
breeds containing < 10 dogs and/or < 5 DM cases were
classified as purebred (other). Age was determined at the
“date of diagnosis” and categorised into quartiles that
grossly corresponded to 3 to < 8, 8 to < 10, 10 to < 13,
and > 13 years. Adult mean bodyweight was calculated
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from all bodyweight data recorded from 18months of
age for each dog and used to classify dogs as at/above or
below their breed/sex mean value. Veterinary group was
categorised A – E; each group consisted of clinics that
were part of the same parent company. The clinical re-
cords were examined manually to extract data on obesity,
systemic glucocorticoid treatment within 6 weeks prior to
diagnosis, or concurrent (+/− 3months of diagnosis) diag-
nosis of pancreatitis or hyperadrenocorticism. Presence of
obesity was recorded when there was evidence of a veter-
inary surgeon/nurse classifying the dog as very overweight,
obese, or BCS ≥ 4/5 or ≥ 8/10, either at diagnosis or within
the preceding 12months. Evidence of pancreatitis was de-
termined by a final veterinary diagnosis of pancreatitis, or
a canine pancreatic lipase immunoreactivity of ≥400 μg/l.
A diagnosis of hyperadrenocorticism included any dog ini-
tiated on trilostane treatment. Evidence for these latter
two conditions was extended to +/− 3months of diagnosis
to account for similarities to DM in presenting signs, and
unreliability of some hyperadrenocorticism tests in un-
stable diabetic dogs [50].
Survival analysis
Survival analysis additionally included variables describ-
ing which diagnostic tests were used (urinalysis, BG,
fructosamine, unspecified blood tests), BG level at diag-
nosis (as determined by a handheld glucometer, inhouse
blood analyser, or via an external laboratory), evidence
of ketosis at diagnosis (defined as a ketone recording of
≥1 on a urinalysis strip at or within 3 days of presenta-
tion, and prior to initiating insulin treatment), presence
of cataracts within 3months of diagnosis, referral for ad-
vanced clinical management, hospitalisation, initial insu-
lin treatment regime, and management methods for the
first 3 months (home BG measurements, BG curve, fruc-
tosamine, spot BG – defined as no more than one read-
ing taken in 24 h, unspecified blood tests, urinalysis,
recommended diet change). BG level at diagnosis was
split primarily around the median and then 4 categories
were created to reflect divisions of BG from above the
renal threshold value (approx. 11.1 mmol/L) to the
upper limit detected by handheld blood glucometers
(approx. 40 mmol/L). These categories correspond to <
20mmol/L, 20–30mmol/L, 30–40mmol/L, and > 40
mmol/L. Information on the date and cause of all deaths
prior to February 2020 was extracted from the EPR. Re-
cords not explicitly recording death were censored at
the date of the last practice-patient interaction prior to
February 2020. Diabetes mellitus was recorded as the
cause of death for deaths that occurred subsequent to
the worsening of clinical signs. Euthanised cases were
further classified as condition worsening, inability to
cope with condition (owner), financial considerations,
concurrent conditions or other. Data entry errors were
minimised by a secondary coder checking every case and
15% of controls.
Statistical analysis
Data were checked and cleaned in Microsoft Excel be-
fore exporting to Stata for analysis. One-year period
prevalence was calculated as the number of newly diag-
nosed and pre-existing DM cases present in 2016 within
the study population. Annual incidence risk with 95%
confidence interval (CI) was calculated as the proportion
of newly diagnosed DM cases in 2016 within the study
population of dogs ≥3 years old on 01/01/2016.
The case-control study used univariable binary logistic
regression modelling to explore associations between po-
tential risk factors and the development of DM. Vari-
ables with a likelihood ratio test (LRT) of p < 0.2 were
taken forward to multivariable analysis. Where checks
for multicollinearity identifies an association, the variable
with the lowest p-value within the multivariable model
was retained. A manual forward selection method was
used to build the final multivariable logistic regression
model, retaining variables with a likelihood ratio test of
P < 0.05. Final model variables were assessed for pairwise
interaction effects using the LRT, confounding was
assessed by evaluating for a > 10% change in parameter
estimates, and all confounders were included in the final
model. Clustering at the veterinary practice level was
evaluated by including clinic ID as a random effect.
Model fit was assessed using the Hosmer-Lemeshow test
statistic [51], and statistical significance was set at 5%.
Median survival time was calculated for all-cause mor-
tality, defined as the time from DM diagnosis until the
cumulative survival proportion reached 50% [52]. Me-
dian survival time was calculated for all dogs, and also
for a subset of dogs that survived at least day 7 following
diagnosis. Cox regression modelling was used to assess
associations with survival for all dogs. Variables associ-
ated with survival (P < 0.2) in the univariable analysis
were taken forward to the multivariable analysis. Multi-
variable modelling used the same criteria as the logistic
regression. Clinic ID was included as a frailty term to
evaluate clustering at the practice level. The proportional
hazards assumption was evaluated with Schoenfeld re-
siduals and visual inspection of the Nelson-Aalen cumu-
lative hazard plot. Statistical significance was set at 5%.
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